Paladin: New Carotid Protection System with Good Results

Courtesy of Dr. Carlos Fava. Carotid artery stenting (CAS) with a cerebral protection system has emerged as an alternative to surgery, particularly for patients with high surgical risk. Nowadays, there are a considerable number of cerebral protection systems, but these may sometimes fail due to anatomical issues, the diameter of embolized particles, or placement difficulties (among<a href="https://solaci.org/en/2019/03/27/paladin-new-carotid-protection-system-with-good-results/" title="Read more" >...</a>

ACC 2019 | Prometedores resultados para el TAVI en bajo riesgo

ACC 2019 | TAVR in Low-Risk Patients Is Noninferior

Courtesy of Dr. Carlos Fava. Self-expanding supraannular aortic valves have proved to be superior to surgery in high-risk patients and noninferior in intermediate-risk patients. However, the current challenge is posed by low-risk, generally younger, patients. In that sense, our purpose is to determine device effectiveness and safety in terms of mortality and stroke rates (which are<a href="https://solaci.org/en/2019/03/19/acc-2019-tavr-in-low-risk-patients-is-noninferior/" title="Read more" >...</a>

Abluminal Sirolimus and luminal CD34 antibody layer: Is COMBO the Future of Stents?

This large cohort of patients treated with the dual therapy COMBO stent has showed excellent outcomes after one year (MASCOT Post Marketing Registry). Long term follow up is still ongoing. The COMBO stent is a new device with an abluminal sirolimus biodegradable polymer and a luminal layer of antibodies that promotes endothelial healing (anti CD34+)<a href="https://solaci.org/en/2019/03/11/abluminal-sirolimus-and-luminal-cd34-antibody-layer-is-combo-the-future-of-stents/" title="Read more" >...</a>

The 10 Most Read Articles of January

1- These Were the Most Relevant Article of 2018 in the Field of Coronary Diseases Read the best articles on coronary heart disease from 2018 at solaci website. Read more   2- The 10 Commandments of ESC’s New STEMI Guidelines The authors have given an entertaining account of the most relevant points and differences between<a href="https://solaci.org/en/2019/02/15/the-10-most-read-articles-of-january/" title="Read more" >...</a>

“Troponinitis” or “Troponinemia”: Terms that Trivialize Troponin Elevation Without a Specified Diagnosis

Troponin elevation is a common finding in acute patients admitted by an emergency service, even in the absence of an acute coronary event. There are patients in whom we simply cannot identify the origin of such troponin elevation. Initially, we relied on this marker as an exclusive marker of acute coronary syndrome. In consequence, many<a href="https://solaci.org/en/2019/01/21/troponinitis-or-troponinemia-terms-that-trivialize-troponin-elevation-without-a-specified-diagnosis/" title="Read more" >...</a>

Los Mejores Artículos de 2018 en Cardiopatía Estructural

The Most Important Articles of 2018 in Structural Heart Diseases

1- ESC 2018 | MITRA FR: Testing MitraClip for Secondary Mitral Regurgitation In secondary mitral regurgitation, mitral-valve leaflets and chordae are structurally normal and mitral regurgitation results from alterations in left ventricular geometry and function. Read more   2- TCT 2018 | COAPT: MitraClip in Patients with Secondary Mitral Regurgitation The prognosis of patients with<a href="https://solaci.org/en/2019/01/18/the-most-important-articles-of-2018-in-structural-heart-diseases/" title="Read more" >...</a>

The 10 most consulted articles at SOLACI during 2018

1- New High Blood Pressure Guidelines The wait is finally over: the high blood pressure guidelines that have been in the works for the past 3 years saw the light of day at the American Heart Association (AHA) 2017 Scientific Sessions. Read more   2- The 10 Commandments of ESC’s New STEMI Guidelines The authors<a href="https://solaci.org/en/2019/01/08/the-10-most-consulted-articles-at-solaci-during-2018/" title="Read more" >...</a>

Early Strut Coverage and Its Implications for Dual Antiplatelet Therapy

Optical coherence tomography (OCT)-guided drug-eluting stent implantation improves early strut coverage compared with angiography-guided angioplasty. No difference was observed in terms of strut coverage between permanent-polymer everolimus-eluting stents and bioresorbable-polymer biolimus-eluting stents. Short-term dual antiplatelet therapy may be feasible in selected patients with early strut coverage.   This study sought to measure early strut coverage<a href="https://solaci.org/en/2018/12/14/early-strut-coverage-and-its-implications-for-dual-antiplatelet-therapy/" title="Read more" >...</a>

Can We Discontinue Betablockers after AMI?

Betablockers (BB) were the first drugs shown to effectively reduce events after acute MI. However, reperfusion and other secondary prevention drugs that came along after that have cast a shadow on betablockers’ original benefit. This study looked at betablocker discontinuation after acute MI in patients with no cardiac failure optimally treated with all recommended medication.<a href="https://solaci.org/en/2018/12/10/can-we-discontinue-betablockers-after-ami/" title="Read more" >...</a>

AHA 2018 | DES de última generación similares a los de 2° generación más allá del polímero

AHA 2018 | New-Generation DES Are Similar to Second-Generation DES Beyond Polymer

Sirolimus-eluting stents with biodegradable polymer did not offer better outcomes compared with instant-classic (and undoubtedly valid) everolimus-eluting stents with durable polymer such as Xience. New-generation drug-eluting stents (DES) offer better outcomes than first-generation devices after a 10-year follow-up, according to the ISAR-TEST 4 trial presented at the American Heart Association (AHA) Congress Scientific Sessions and published<a href="https://solaci.org/en/2018/11/30/aha-2018-new-generation-des-are-similar-to-second-generation-des-beyond-polymer/" title="Read more" >...</a>

acute myocardial infarction